Canada markets closed

Certara, Inc. (CERT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.93-0.28 (-1.73%)
At close: 04:00PM EDT
15.93 0.00 (0.00%)
After hours: 04:13PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close16.21
Open16.24
Bid15.90 x 100
Ask15.95 x 100
Day's Range15.83 - 16.32
52 Week Range11.81 - 24.70
Volume578,031
Avg. Volume553,877
Market Cap2.552B
Beta (5Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform

    PRINCETON, N.J., April 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates its many scientific software solutions. Customers log into Certara Cloud using a single ID to access and manage their licensed software, linking predictive solutions to modeling and analysis of clinical trial results. "This reusable suite of shared platform services enables us to bo

  • GlobeNewswire

    Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference

    PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara al

  • GlobeNewswire

    Certara Reports Fourth Quarter 2023 Financial Results

    Provides Full Year 2024 Financial GuidancePRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023. Fourth Quarter Highlights: Revenue was $88.0 million, compared to $86.6 million in the fourth quarter of 2022, representing growth of 2% over the fourth quarter of 2022.Strong sequential growth with record software bookings and broad-based recovery in technology